Примери за използване на Combination products на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
These combination products are also being removed.
Not relevant as used in combination products only.
Combination products containing domperidone/cinnarizine.
Previous CVMP conclusions applicable to colistin combination products.
For fixed dose combination products containing metformin.
Хората също превеждат
For non-gastrointestinal indications there are concerns of lack of justification for colistin combination products.
Such combination products should always be regulated under this Regulation.
Additionally, pharmacovigilance data have revealed no reports of lack of efficacy for colistin combination products.
Some of these combination products now have as much as 750 mg of acetaminophen per dose.
Therefore, the CVMP concluded that no gastrointestinal indications could be supported for colistin combination products.
Several fixed-dose combination products containing metformin are available in Europe(see below).
Food enzymes are available as supplements,as separate constituents, or in combination products that combine more than one enzyme.
Combination products contain 2 or more different active ingredients that have a stronger effect when combined.
The CVMP considered that the end result of using colistin combination products instead of monotherapy is an unnecessary use of colistin.
Combination products are also approved, but this procedure focused on the assessment of the monocomponent products. .
Rigana is one of the preferred suppliers to the Bulgarian meat processing industry of flavoring mixtures,spices and other combination products.
Sales of combination products with colistin represented less than 10% of the overall sales of colistin(ESVAC, unpublished data).
As the scope of the current referral was restricted to the evaluation of flukicidal substances,the second active substances in combination products were not assessed.
And combination products, such as Ester-C®, which contains calcium ascorbate, dehydroascorbate, calcium threonate, xylonate and lyxonate.
Ambroxol- and bromhexine-containing medicines are marketed as single products or as fixed combination products with various other active ingredients.
In conclusion, colistin combination products are intended to address different clinical needs to monotherapy products. .
It should be noted that many(155) of the clorsulon, closantel, nitroxinil, rafoxanide ortriclabendazole containing products are combination products containing other active substances.
The use of combination products represents a risk of unnecessary use of colistin in cases where no additional benefit has been shown over the use of one substance alone.
Thus, the use of colistin in foals is considered to present a serious risk in relation to target animal safety andfoals cannot be supported as a target animal species for colistin combination products.
Some fixed-dose combination products are still not recommended in patients with moderately reduced kidney function because the other active substance in the combination should not be used in these patients.
However, veterinary medicinal products containing closantel administered as pour-on and authorised in the Member States(EU/EEA)are all combination products containing ivermectin as second active substance.
Colistin combination products are seen to serve a role for these more complex production-related diseases and clinical studies are available for some combinations, which demonstrated efficacy for some conditions.
However, veterinary medicinal products containing clorsulon administered subcutaneously authorised in the in the Member States(EU/EEA)are all combination products containing ivermectin as second active substance.
The European Commission asked the CHMP to carry out a full assessment of the benefit-risk balance of combination products containing dextropropoxyphene and paracetamol and to issue an opinion on whether the marketing authorisations for these medicines should be maintained, varied.
The compatibility of the active substance with excipients as well as key physicochemical characteristics of the active substance that can influence the performance of the finished product orthe compatibility of different active substances with each other in the case of combination products, shall be documented.